.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Best Practices for Advancing Treatments in Newly Diagnosed and Relapsed/Refractory MM

EP. 1: Dr Krishnan on Maintenance Approaches in Transplant-Ineligible Multiple Myeloma

August 29th 2024

Amrita Krishnan, MD, discusses maintenance therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma.

EP. 2: Dr Usmani on Challenges With Bispecifics and CAR T-Cell Therapies in Multiple Myeloma

October 3rd 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses challenges of integrating bispecific antibodies and CAR T-cell therapies into the community for myeloma.

EP. 3: Dr Chari on the Risks and Benefits Associated With Earlier CAR T Use in R/R Multiple Myeloma

October 4th 2024

Ajai Chari, MD, discusses the potential role for CAR T-cell therapies in the early-relapsed setting for patients with multiple myeloma.